Adaptin Bio (APTN) Return on Capital Employed (2024 - 2026)

Adaptin Bio (APTN) has 3 years of Return on Capital Employed data on file, last reported at 313.83% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 102634.0% year-over-year to 313.83%; the trailing twelve-month figure through Mar 2026 stood at 313.83% (up 102634.0% YoY), and the FY2025 full-year result was 322.46%, up 26156.0% from the prior year.
• Return on Capital Employed slipped to 313.83% in Q1 2026, from 413.59% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 890.69% in Q3 2024 to a low of 712.52% in Q1 2025.
• A 3-year average of 250.64% and a median of 363.71% in 2025 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed tumbled 91843 bps in 2025 and jumped 102634 bps in 2026, its largest moves.
• Tracing APTN's Return on Capital Employed over 3 years: stood at 60.9% in 2024, then soared by 579 bps to 413.59% in 2025, then fell by 24 bps to 313.83% in 2026.
• Business Quant data shows APTN's Return on Capital Employed at 313.83% in Q1 2026, 413.59% in Q4 2025, and 844.31% in Q3 2025.